Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist.

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Abstract Text:

Kristi A Sacco,Angelo Termine,Melissa M Dudas,Aisha A Seyal,Taryn M Allen,Jennifer C Vessicchio,Bruce E Wexler,Tony P George,

BACKGROUND: Biochemical, physiological and genetic evidence suggests dysregulation of central nicotinic acetylcholine receptor (nAChR) systems in schizophrenia, which may contribute to neuropsychological dysfunction and the high rates of smoking in this disorder. To evaluate the effects of nAChR blockade on neuropsychological performance in schizophrenia without the confounding effects of cigarette smoking, we compared neuropsychological performance in schizophrenia and healthy control nonsmokers after pre-treatment with the centrally-acting nAChR antagonist mecamylamine (MEC). METHODS: Using a within-subjects, counterbalanced design, schizophrenia (n = 14) and control (n = 15) nonsmokers were pre-treated for 3 days with MEC (0.0, 5.0, and 10.0 mg/day). Subjects performed repeated neuropsychological assessments including visuospatial working memory (VSWM), Continuous Performance Test (CPT), Wisconsin Card Sorting Test (WCST), Word Serial Position Test (WSPT) and Stroop Color Word Test (SCWT) during three sequential test sessions per week over three test weeks. RESULTS: We found significant main effects of schizophrenia diagnosis on: VSWM 30 and 60 delays (p's < 0.01), CPT (% Hit Rate, Reaction Time, Variability Index; p < 0.01 for all outcomes), WCST (p < 0.01 for all outcomes) and Word Serial Position Test (p < 0.01). However, there were no main effects of repeated test administration (Session) or MEC dose on any of these outcomes, and no significant 3-way (DiagnosisxSessionxMEC dose) interactions. CONCLUSIONS: Our results suggest that there are a broad range of neuropsychological deficits in nonsmokers with schizophrenia. Furthermore, pretreatment with a centrally-acting nAChR antagonist did not alter neuropsychological performance in either nonsmoking patients with schizophrenia or controls.

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Publishing Authors By Initials

KA Sacco,A Termine,MM Dudas,AA Seyal,TM Allen,JC Vessicchio,BE Wexler,TP George,

For similar psychological phenomena and processes: mental processes: perception: visual perception research abstracts see: psychological phenomena and processes: mental processes: perception: visual perception research

PUBMED ID PMID:

MEDLINE DATE:

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Schizophrenia research

VOLUME: 85

Page Numbers: 213-21

Journal Abbreviation: Schizophr. Res.

ISSN: 0920-9964

DAY: 4

MONTH: 05

YEAR: 2006

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8804207

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Keywords Mesh Terms:

KEYWORDS: Visual Perception

MESH TERMS: drug effects

Chemical & Substance for Abstract: Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Information

Substance Name: Mecamylamine

Registry Number: 60-40-2

Grant and Affiliation Information for Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist.

AFFILIATION: Program for Research in Smokers with Mental Illness (PRISM), Yale University School of Medicine, New Haven, CT 06519, USA. kristi.sacco@yale.edu

Country: Netherlands

AGENCY: United States NIDA

GRANT: R01-DA-14039

ACRONYM: DA

MEDLINETA: Schizophr Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist Related Publications

• A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model.
• ADCS Prevention Instrument Project: pilot testing of a book club as a psychosocial intervention and recruitment and retention strategy.
• Acute left prefrontal transcranial magnetic stimulation in depressed patients is associated with immediately increased activity in prefrontal cortical as well as subcortical regions.
• Airway nitric oxide release is reduced after PBS inhalation in asthma.
• Alcohol and sexuality research in the AIDS era: trends in publication activity, target populations and research design.
• Bilateral nephrectomy for treatment resistant systemic lupus erythematosis and thrombotic thrombocytopenic purpura: a case report.
• Biological markers for evaluation of root resorption.
• Computerized local dental anesthetic systems: patient and dentist satisfaction.
• Couple and individual adjustment for 2 years following a randomized clinical trial comparing traditional versus integrative behavioral couple therapy.
• Current standard and investigational approaches to the management of hormone-refractory prostate cancer.
• D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum.
• Developmental toxicity evaluation of berberine in rats and mice.
• Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.
• Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis.
• Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry.
• Familial hypodysfibrinogenaemia associated with second occurrence of gamma326 Cys-->Tyr mutation.
• Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
• Impaired inactivation gate stabilization predicts increased persistent current for an epilepsy-associated SCN1A mutation.
• Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
• Mitochondrial DNA variation within and among regional populations of longtail macaques (Macaca fascicularis) in relation to other species of the fascicularis group of macaques.
• Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist.
• Nonfunctional SCN1A is common in severe myoclonic epilepsy of infancy.
• Noninvasive assessment of collagen gel microstructure and mechanics using multiphoton microscopy.
• PiggyBac Transposon-mediated Gene Transfer in Human Cells.
• Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.
• Reliability of the Fagerström Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia.
• Structure of the active site of sulfite dehydrogenase from Starkeya novella.
• The efficacy of duloxetine in the treatment of premature ejaculation.
• The international movement of livestock.
• Use of bone morphogenetic protein-2 and dentin matrix protein-1 to enhance the osteointegration of the Onplant system.